5077892026-09-235077892026-09-232026-09-23iso4217:INRxbrli:pure507789JAGSONPAL PHARMACEUTICALS LIMITEDJAGSNPHARMNOTLISTEDINE048B01035NewAcquisition (including agreement to acquire)false2026-09-2317:42:002026-09-23JAGSONPAL PHARMACEUTICALS LIMITEDListed Entity (self)Group Pharma (Wellness Portfolio)252000000629000003801600000falsefalsetruePharmaceuticalsThe acquisition will strengthen the Company’s pharmaceutical portfolio, expand its presence across relevant therapeutic segments and enhance market reach.Notrue01/11/2026Cash460700000Initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of upto ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores.00Not applicable. The Company proposes to acquire the Wellness Portfolio of Group Pharmaceuticals Limited, which is engaged in the pharmaceutical business, on a going-concern basis by way of slump sale. The business has presence in India and comprises the identified products, assets, contracts, employees and other arrangements relating to the businessIndiaSince the Company has acquired the portfolio from the seller, we have reported EBITDA instead of PAT. Further, the information required under ‘Cost of Acquisition’ or ‘Price at which shares have been acquired’ has been disclosed as ‘0’, as this transaction pertains solely to the acquisition of a product portfolio through cash consideration